Mansfield, MA (November 6, 2014): New England Controls announced a new partnership agreement with CONTINUUS Pharmaceuticals, a revolutionary spin-out company from the Massachusetts Institute of Technology (MIT). This agreement will create a path for CONTINUUS to bring their Integrated Continuous Manufacturing (ICM) process to the life sciences marketplace through the DeltaV™ digital automation system and Syncade™ manufacturing execution system (MES).

The DeltaV™ system controls each step of the ICM process, while Syncade™ provides instructions to the operator so that the necessary actions are completed correctly and at the right time. By implementing the innovative CONTINUUS technology, pharmaceutical manufacturers can eliminate the step-by-step requirements of a traditional batch process. Instead, they can apply an integrated, continuous manufacturing methodology that simplifies the path from raw materials used in the synthesis of the active ingredient to the final dosage form. Pharmaceutical manufacturers can produce medicines at significantly reduced costs (50% reduction), with reduced lead times (90% reduction from industry standard), and of better quality.

“CONTINUUS Pharmaceuticals’ breakthrough ICM technology for the life science industry is positioned to be a catalyst for change in an industry which operates exclusively in a batch environment,” said Mark Genest, senior account manager with New England Controls. “This technology will have a positive impact in both time to market and cost of manufacturing for those companies using it.”

“We have undertaken the most revolutionary approach to continuous manufacturing, where a set of new process technologies runs simultaneously, under fully automated control, from the beginning to the end of the process. This requires complex automation and an integrated control strategy of our plants. The partnership with New England Controls will provide us with advanced and flexible control architecture for our processes, and we are very excited about our collaboration,” said Salvatore Mascia, Founder and CEO of CONTINUUS Pharmaceuticals.

“New England Controls is excited to partner with CONTINUUS Pharmaceuticals. The DeltaV™ process automation system and Syncade™ manufacturing execution system will be engineered to enable the rapid deployment of the ICM process providing significant ‘on-demand’ manufacturing advantages to their customers,” said Tom Ramundo, President of New England Controls.

CONTINUUS will initially utilize the Guest Center at New England Controls’ headquarters in Mansfield, Massachusetts to provide a location for customer demonstrations of the ICM process via a DeltaV™ simulation system. In the future, a full-scale DeltaV™ development system is planned to be installed in CONTINUUS’ pilot plant in Woburn, Massachusetts.

About New England Controls

New England Controls delivers a broad scope of products along with the engineering, training, maintenance and asset reliability services required to solve process control needs. As a Local Business Partner of Emerson Process Management, New England Controls serves the life sciences, power generation, pulp & paper, gas distribution & transmission, water & wastewater and various other industries.

Learn more at: